FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J Suppl / Equine recurrent uveitis: the European viewpoint.
Equine veterinary journal. Supplement2010; (37); 50-56; doi: 10.1111/j.2042-3306.2010.tb05635.x

Equine recurrent uveitis: the European viewpoint.

Abstract: Equine recurrent uveitis (ERU) has always been and still is an important disease with a significant impact on the horse industry in Europe, with a prevalence of 8-10%. The need to understand and manage the disease has spurred the development of veterinary ophthalmology in general, although the aetiology of the disease remains the subject of intense discussion. It is most probably an autoimmune disease triggered, at least in Europe, in the majority of cases by Leptospira spp. The therapy of ERU has evolved over the centuries from various methods of bloodletting to rational medical therapy using mydriatics and steroidal and nonsteroidal anti-inflammatory drugs, to surgical therapies, such as vitrectomy or implantation of cyclosporin-releasing devices. In Europe, pars plana vitrectomy in horses testing positive for Leptospira spp. appears to be the most successful form of therapy at the present time.
Get Full Text
Publication Date: 2010-10-14 PubMed ID: 20939167DOI: 10.1111/j.2042-3306.2010.tb05635.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research focuses on Equine recurrent uveitis (ERU), a prevalent disease impacting the horse industry in Europe, believed to be primarily triggered by Leptospira spp. The study elaborates on the various therapeutic strategies used to manage ERU, with Pars plana vitrectomy seemingly the most effective for horses testing positive for Leptospira spp.

Understanding Equine recurrent uveitis (ERU)

  • ERU is a key disease that significantly impacts the horse industry in Europe. The prevalence of ERU is quite high, estimated to be between 8-10%.
  • The disease’s exact cause is still under intense debate. Current understanding points towards ERU being an autoimmune condition. In Europe, a majority of ERU cases are triggered by an organism called Leptospira spp.

Proliferation of Veterinary Ophthalmology

  • The imperative to effectively diagnose, manage, and treat ERU has spurred the growth of veterinary ophthalmology, although the mystery around its exact aetiology still persists. The disease’s unpredictable and recurring nature makes it a complex problem in veterinary medicine.
  • ERU presumably kick starts an autoimmune response that involves the eye. This misguided immune response damages the ocular tissue, causing inflammation and, in severe cases, leading to blindness.

Progression of ERU Treatment

  • Over the centuries, the therapeutic strategy for managing ERU has evolved drastically. Initial practices involved methods of bloodletting, a now largely debunked and abandoned practice in modern medicine.
  • With medical advancements, the treatment shifted towards rational medical therapy using mydriatics, steroidal and non-steroidal anti-inflammatory drugs.

Surgical Therapies

  • Over time, surgical therapies have also been developed and adopted. These include vitrectomy, a surgical procedure to remove the vitreous humor from the eye, and implantation of cyclosporin-releasing devices which help suppress the immune response.
  • As of now, Pars plana vitrectomy, a specific type of vitrectomy, is the most successful form of therapy for horses testing positive for Leptospira spp. in Europe.

Cite This Article

APA
Spiess BM. (2010). Equine recurrent uveitis: the European viewpoint. Equine Vet J Suppl(37), 50-56. https://doi.org/10.1111/j.2042-3306.2010.tb05635.x

Publication

Equine veterinary journal. Supplement
NlmUniqueID: 9614088
Country: United States
Language: English
Issue: 37
Pages: 50-56

Researcher Affiliations

Spiess, B M
  • Veterinary Ophthalmology Service, Equine Department, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland.

MeSH Terms

  • Animals
  • Europe / epidemiology
  • Horse Diseases / epidemiology
  • Horse Diseases / pathology
  • Horse Diseases / therapy
  • Horses
  • Recurrence
  • Uveitis / epidemiology
  • Uveitis / pathology
  • Uveitis / therapy
  • Uveitis / veterinary

Citations

This article has been cited 18 times.
  1. Arshad A, Reif AH, Cavalleri JV, Desvars-Larrive A. Zoonotic pathogens in equids in Central Europe: a systematic review. BMC Vet Res 2025 Jul 8;21(1):451.
    doi: 10.1186/s12917-025-04915-5pubmed: 40629389google scholar: lookup
  2. Ing ST, Pinard CL, James-Jenks EM, Leis ML. A retrospective survey of equine ocular diseases evaluated at a referral hospital in Ontario (2011 to 2021). Can Vet J 2025 Mar;66(3):308-317.
    pubmed: 40070935
  3. Fleischer AB, Amann B, von Toerne C, Degroote RL, Schmalen A, Weißer T, Hauck SM, Deeg CA. Differential Expression of ARG1 and MRC2 in Retinal Müller Glial Cells During Autoimmune Uveitis. Biomolecules 2025 Feb 14;15(2).
    doi: 10.3390/biom15020288pubmed: 40001591google scholar: lookup
  4. Kalinovskiy A, Leser S, Ehrle A, Reese S, Jones S, Gerhards H. Phacoemulsification Combined with Pars Plana Vitrectomy: Outcome in Horses with Acquired Cataracts Associated with Uveitis. Animals (Basel) 2024 Apr 16;14(8).
    doi: 10.3390/ani14081192pubmed: 38672339google scholar: lookup
  5. Morén S, Kallberg M, Strom L. Equine uveitis: Outcome and adverse effects after one or two intravitreal low-dose gentamicin injections. Equine Vet J 2025 Jan;57(1):160-168.
    doi: 10.1111/evj.14056pubmed: 38329024google scholar: lookup
  6. Crabtree E, Uribe K, Smith SM, Roberts D, Salmon JH, Bower JJ, Song L, Bastola P, Hirsch ML, Gilger BC. Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy. PLoS One 2022;17(8):e0270972.
    doi: 10.1371/journal.pone.0270972pubmed: 35980983google scholar: lookup
  7. Wollanke B, Gerhards H, Ackermann K. Infectious Uveitis in Horses and New Insights in Its Leptospiral Biofilm-Related Pathogenesis. Microorganisms 2022 Feb 7;10(2).
    doi: 10.3390/microorganisms10020387pubmed: 35208842google scholar: lookup
  8. Wasiński B, Paschalis-Trela K, Trela J, Czopowicz M, Kita J, Żychska M, Cywińska A, Markowska-Daniel I, Carter C, Witkowski L. Serological Survey of Leptospira Infection in Arabian Horses in Poland. Pathogens 2021 Jun 1;10(6).
    doi: 10.3390/pathogens10060688pubmed: 34206112google scholar: lookup
  9. Ström L, Dalin F, Domberg M, Stenlund C, Bondesson U, Hedeland M, Toutain PL, Ekstrand C. Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. BMC Vet Res 2021 Apr 7;17(1):149.
    doi: 10.1186/s12917-021-02847-4pubmed: 33827566google scholar: lookup
  10. Degroote RL, Deeg CA. Immunological Insights in Equine Recurrent Uveitis. Front Immunol 2020;11:609855.
    doi: 10.3389/fimmu.2020.609855pubmed: 33488614google scholar: lookup
  11. Crabtree E, Song L, Llanga T, Bower JJ, Cullen M, Salmon JH, Hirsch ML, Gilger BC. AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis. Sci Rep 2019 Dec 27;9(1):19864.
    doi: 10.1038/s41598-019-56462-3pubmed: 31882729google scholar: lookup
  12. Slenter IJM, Hermans H, Ensink JM, Willems DS, Veraa S, Grinwis GCM, Boevé MH. Clinical, ultrasonographic, and histopathologic findings in seven horses with Descemet's membrane detachment: A case series. Vet Ophthalmol 2020 Jan;23(1):181-189.
    doi: 10.1111/vop.12710pubmed: 31544302google scholar: lookup
  13. Fischer BM, McMullen RJ Jr, Reese S, Brehm W. Intravitreal injection of low-dose gentamicin for the treatment of recurrent or persistent uveitis in horses: Preliminary results. BMC Vet Res 2019 Jan 16;15(1):29.
    doi: 10.1186/s12917-018-1722-7pubmed: 30651102google scholar: lookup
  14. Paschalis-Trela K, Cywińska A, Trela J, Czopowicz M, Kita J, Witkowski L. The prevalence of ocular diseases in polish Arabian horses. BMC Vet Res 2017 Nov 7;13(1):319.
    doi: 10.1186/s12917-017-1252-8pubmed: 29115950google scholar: lookup
  15. Malalana F, Blundell RJ, Pinchbeck GL, Mcgowan CM. The role of Leptospira spp. in horses affected with recurrent uveitis in the UK. Equine Vet J 2017 Nov;49(6):706-709.
    doi: 10.1111/evj.12683pubmed: 28321895google scholar: lookup
  16. Degroote RL, Hauck SM, Amann B, Hirmer S, Ueffing M, Deeg CA. Unraveling the equine lymphocyte proteome: differential septin 7 expression associates with immune cells in equine recurrent uveitis. PLoS One 2014;9(3):e91684.
    doi: 10.1371/journal.pone.0091684pubmed: 24614191google scholar: lookup
  17. Kulbrock M, Lehner S, Metzger J, Ohnesorge B, Distl O. A genome-wide association study identifies risk loci to equine recurrent uveitis in German warmblood horses. PLoS One 2013;8(8):e71619.
    doi: 10.1371/journal.pone.0071619pubmed: 23977091google scholar: lookup
  18. Swadzba ME, Hauck SM, Naim HY, Amann B, Deeg CA. Retinal glycoprotein enrichment by concanavalin a enabled identification of novel membrane autoantigen synaptotagmin-1 in equine recurrent uveitis. PLoS One 2012;7(12):e50929.
    doi: 10.1371/journal.pone.0050929pubmed: 23236410google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.